Moreover, the profile differences of key immune checkpoint genes expressed in the MPS-I and MPS-II NB samples were examined and it was found that the high expression of lymphocyte-activating gene 3 (LAG3) in MPS-II NB indicated that immunotherapy targeting LAG3 could be beneficial for the clinical treatment of patients with MPS-II (Figure 6 D and Result S3). Here, LAG3 is linked to mucopolysaccharidosis type 2.